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Abstract
Introduction: Autoantibodies in patients with polymyositis/dermatomyositis (PM/DM) are associated with unique
subsets, clinical course and outcome. Anti-MJ antibodies, which recognize the nuclear protein NXP-2/MORC3, are
reported in ~25% of juvenile DM. Prevalence and clinical significance of anti-MJ antibodies in adult Italian PM/DM
patients were studied.
Methods: Sera from 58 consecutive adult Italian PM/DM patients were analyzed by immunoprecipitation of 35S-
labeled K562 cells extract, ELISA (anti-MJ, Jo-1), Western blot and indirect immunofluorescence. Clinical associations
were analyzed using information from medical charts.
Results: Anti-MJ antibodies were the most prevalent specificity (17%) found mainly in DM (30%, 8 cases) vs 8% of
PM (2 cases, P = 0.02). Comparing 10 anti-MJ (+) vs 48 anti-MJ (-) cases, DM was more common (P = 0.03), and
age at onset was younger in anti-MJ (+) (P = 0.0006). In anti-MJ (+), heliotrope rash (P = 0.01) and calcinosis (P =
0.09) were more frequent. None of them had heart or lung involvement, or malignancy. Myopathy in anti-MJ (+)
patients responded well to therapy and none of them had elevated CPK at last visit (0% vs 25% in anti-MJ (-)).
Only 60% of anti-MJ (+) showed immunofluorescent nuclear dots staining, despite PML localization of NXP-2/
MORC3.
Conclusions: Anti-MJ antibodies are the most frequent specificity in our cohort of adult Italian PM/DM. Anti-MJ (+)
were associated with young onset DM, calcinosis, no internal organ involvement and good response of myopathy
to therapy. Anti-MJ reported in juvenile DM is also found in adult PM/DM, and could be a new useful biomarker.
Introduction
Myositis-specific autoantibodies (MSAs) are helpful in
the diagnosis of polymyositis/dermatomyositis (PM/
DM), in identifying distinct clinical subsets, and disease
monitoring [1-3]. MSAs, including antibodies to ami-
noacyl-tRNA synthetases (Jo-1 is the most frequent),
anti-p155/140, -CADM-140, -Mi-2, and -SRP are gener-
ally found in ~50% of adults with PM/DM [3]. Since
many patients do not have known MSAs, it is important
to characterize additional autoantibodies in PM/DM,
and to clarify their clinical significance. A new
autoantibody, called anti-MJ, has been identified in juve-
nile DM (JDM) patients [4,5], and it was associated with
severe muscle weakness, polyarthritis, joint contractures,
and intestinal vasculitis [4]. In a cohort of Argentine
pediatric myositis patients, anti-MJ antibodies were the
most prevalent specificity (25% of cases), associated with
muscle contracture, atrophy and significant compromise
of the functional status [6]. The target of anti-MJ anti-
bodies was identified as a nuclear protein called NXP-2
[7], which plays important roles in diverse nuclear func-
tions, including RNA metabolism and maintenance of
nuclear architecture [7]. NXP-2 (also known as
MORC3) [8,9] localizes in the PML (promyelocytic leu-
kemia) nuclear bodies, where it recruits and activates
p53 to induce cellular senescence [8,10]. The presence
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of anti-MJ antibodies in adult patients with myositis has
been described in an abstract analyzing a British cohort
[11] and in a recent paper showing a possible link
between anti-MJ antibodies and higher risk of malig-
nancy in a Japanese cohort of adult PM/DM patients
[12]. It is also still unclear whether anti-MJ is found in
adult PM/DM has same clinical significance as JDM.
The aim of our study is to analyze the prevalence and
clinical significance of anti-MJ antibodies in a cohort of
adult Italian PM/DM patients.
Materials and methods
Patients
Fifty-eight consecutive adult Italian patients with PM/
DM, who visited the Rheumatology Unit of Spedali
Civili (Brescia, Italy) from 2009 to 2011, were studied.
The diagnosis of PM/DM was based on Bohan and
Peter criteria [13]. Clinical information was obtained
from medical records. The study was approved by the
Institutional Review Board of the hospital. This study
meets, and is in compliance with, all ethical standards of
medicine, and informed consent was obtained from all
patients in accordance with the Declaration of Helsinki.
Immunoprecipitation (IP)
Autoantibodies in sera were screened by IP using 35S-
methionine-labeled K562 cell extract [14]. Specificities
of autoantibodies were determined using reference sera.
ELISA
Anti-MJ antibodies were also tested by antigen-capture
ELISA [15]. Briefly, a 96-well plate Immobilizer Amino
(Nalge Nunc International, Rochester, NY, USA) was
incubated with 50 μl/well of 2 μg/ml mouse monoclonal
antibody (mAb) to MORC3 (MBL International,
Woburn, MA, USA). Wells were then incubated with
K562 cell extract, followed by 1:500 diluted sera, and
probed with alkaline phosphatase conjugated mouse
mAb anti-human Immunoglobulin G (1:2000 dilution)
(Sigma, St. Louis, MO, USA). Anti-Ro52, -La [16,17],
and -Jo-1 (Abazyme, Needham, MA, USA) antibodies
were tested by ELISA using recombinant protein at
1:500 serum dilution. Optical density (OD) of the sam-
ples was converted into units using a standard curve
created by a prototype positive serum [15].
Immunoprecipitation - Western Blot (IP-Western)
Candidates for anti-MJ were selected based on immuno-
precipitation of a 140 kDa protein that comigrates with
MORC3 protein recognized by mAb. Identity of the 140
kDa proteins corresponding to MJ/MORC3/NXP-2 was
verified by IP-Western [14]. Cell extract from 107 K562
cells was immunoprecipitated by candidate sera. Pro-
teins were fractionated by 8% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to a nitrocellulose filter. The filter was
probed with 0.4 μg/ml of anti- MORC3 mouse mAb,
followed by horseradish peroxidase (HRP) goat anti-
mouse IgG (1: 7,500 dilution) (Southern Biotechnology,
Birmingham, AL, USA) and developed using SuperSignal
West Femto chemiluminescent substrate (Thermo
Scientific, Barrington, IL, USA).
Indirect immunofluorescence (IIF)
Immunofluorescent antinuclear/cytoplasmic antibodies
(HEp-2 antinuclear antibody (ANA) slides) (INOVA
Diagnostics, San Diego, CA, USA) were tested using a
1:80 dilution of human sera, or 4 μg/ml of anti-MORC3
mAb followed by DyLight 488 donkey IgG F(ab)’2 anti-
human IgG or goat anti-mouse IgG (1:100 dilution)
(Jackson ImmunoResearch, West Grove, PA, USA).
Double staining was also performed using rabbit anti-
PML antiserum (1:300 dilution) [18] and Alexa 568 goat
anti-rabbit IgG (Invitrogen, Carlsbad, CA, USA).
Statistical analyses
All parameters were analyzed by the Mann-Whitney
test, or Fisher’s exact test between groups using Prism
version 5.0 d for Macintosh (GraphPad Software, Inc.,
La Jolla, CA, USA). Statistical significance was accepted
at P < 0.05.
Results
Demographic data
Fifty-eight patients (43 females, 15 males) with a diagno-
sis of PM (25 cases), DM (27 cases) or overlap syn-
drome (6 cases) were studied. In the whole cohort, the
patients’ age was 52 ± 16 (mean ± standard deviation
(SD)) years, the age at disease onset was 43 ± 17.4 years,
and the mean follow-up was 56 months (range 1 to 288
months).
Autoantibodies
Prevalence of myositis-related autoantibodies by IP in
total PM/DM, DM, and PM is summarized (Table 1).
To our surprise, anti-MJ antibodies were the most pre-
valent specificity (10/58; 17%) in our PM/DM patients,
followed by anti-Jo-1 (10%), -PM-Scl (10%), -U1RNP
(7%), -p155/140 (5%), -SRP (5%), -EJ (3%), -Mi-2 (2%),
and -OJ (2%). Anti-Ro and anti-Su were found in two
cases (3%) each. In 22 patients (38%), no myositis-
related autoantibodies were detected. In DM, no patient
had anti-Jo-1 antibodies, while in PM it was the most
common autoantibody specificity (0% vs 24%; P =
0.0087). Anti-MJ was found only in two cases in PM vs
30% in DM (P = 0.078). Thus, anti-MJ was common in
DM, whereas anti-Jo-1 was found only in PM in our
cohort. Candidates positive for anti-MJ were initially
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selected based on the IP of ~140 kD proteins compared
with molecular weight markers and the mobility of
other known autoantigens (Figure 1A). One of the
known myositis autoantigen CADM140/MDA5, which
migrates close to MJ, is not detectable in our IP system
using K562 cells (Figure 1A, lane MDA5). IP of candi-
dates were then run in SDS-PAGE along with anti-
MORC3 mAb IP. If the mobility of a ~140 kD protein
immunoprecipitated by the serum is considered same as
that of the mAb to MORC3, sera were then tested by
IP-Western to verify their identity as MJ. The 10 anti-
MJ (+) were confirmed by 1) identical mobility of the
140 kDa protein with MORC3 recognized by mAb (Fig-
ure 1B); 2) IP- Western Blot (Figure 1C); and 3) positive
results in antigen-capture ELISA (data not shown).
None of anti-MJ (+) patients had other MSAs, consis-
tent with previous observations [11], though the study
in the Argentinian pediatric cohort reported 2/18 anti-
MJ (+) cases with an additional autoantibody specificity
[6]. NXP-2/MORC3 localizes to nucleus and nuclear
dots, known as PML bodies. Number and intensity of
PML bodies stained by mAb appear to vary depending
on cell type, cell cycle and other factors [10]. In HEp-2
ANA slides, mAb to MORC3 stained nuclei in a fine
speckled pattern with a few nuclear dots (Figure 1D,
panel a). Six (three strong, three weak) of ten anti-MJ
(+) sera showed PML bodies nuclear dots in indirect
immunofluorescence, (Figure 1D, panels b to d), but
PML bodies staining was not clear by other sera (Figure
1D, panel e), indicating that PML bodies immunofluor-
escence cannot be a good method for screening or con-
firmation of anti-MJ specificity.
Clinical and laboratory features
Since anti-MJ antibodies were the most common in
PM/DM (17%) or in DM (30%), clinical features of 10
anti-MJ (+) vs 48 anti-MJ (-) cases were compared
(Table 2). Anti-MJ (+) patients had younger age of dis-
ease onset (25.5 ± 13.8 vs 46.1 ± 15.9 years, mean ± SD,
P = 0.0006 by Mann-Whitney) and age at initial visit
(37.6 ± 12.0 vs 54.6 ± 14.8 years, P = 0.0023 by Mann-
Whitney) compared with anti-MJ (-). Two anti-MJ (+)
patients had pediatric onset DM. DM is more common
in anti-MJ (+) vs (-) (80% vs 40%, P = 0.03) and no
overlap syndrome patients were found in the anti-MJ
group (0% vs 13%). In anti-MJ (+) patients, heliotrope
rash (P = 0.01) and calcinosis (P = 0.09) were common,
but none of them had heart involvement (0% vs 13%),
interstitial lung disease (ILD) (0% vs 33%, P = 0.048), or
malignancy (0% vs 8%). Myopathy in anti-MJ (+)
patients responded well to therapy and elevated creatine
phosphokinase (CPK) was not seen in any patient in the
last visit (0% vs 25%). Thus, anti-MJ antibodies are asso-
ciated with DM of young onset with heliotrope rash and
calcinosis, without cardiac or lung involvement or over-
lapping features, and they respond well to therapy.
Other clinical aspects, such as arthritis and Raynaud’s
phenomenon, were not significantly associated with
anti-MJ antibodies (Table 2). Clinical characteristics of
anti-MJ (+) DM compared to anti-MJ (-) DM were simi-
lar to those shown in Table 2, however, they did not
reach statistical significance due to small numbers;
heliotrope, 75% vs 47%; calcinosis 38% vs 21%; arthritis
25% vs 5%; heart involvement 0% vs 16%; and ILD 0%
vs 32%.
Discussion
Anti-MJ antibodies were originally described as an
abstract in 1997 in a subset of patients with JDM,
characterized by severe muscle involvement [4]. Anti-
MJ was reported in two juvenile DM studies [5,6],
however, its detection in adult PM/DM was only in
the form of an abstract [11] until recently, probably
due to limited availability of the IP assay of this auto-
antibody [6]. A recent study in an adult Japanese
cohort of patients with inflammatory myopathy
reported 1.6% (8/507) prevalence of anti-MJ antibodies
Table 1 Autoantibody prevalence in a cohort of adult




















Anti-Jo-1 10% (6) 02 24% (6)
2
0
Anti-p155/140 5% (3) 7% (2) 0 17% (1)
(DM-SLE-
Sjögren’s)
Anti-SRP 5% (3) 0 8% (2) 17% (1)
(PM-RA)
Anti-EJ 3% (2) 4% (1) 4% (1) 0
Anti-Mi-2 2% (1) 5% (1) 0 0
Anti-OJ 2% (1) 0 4% (1) 0
Anti-PM/Scl 10%(6) 11% (3) 8% (2) 17% (1)
(DM-SSc)
Anti-U1RNP 7% (4) 4% (1) 4% (1) 33% (2)
(DM-SSc; PM-
SLE)
Anti-Ro 3% (2) 0 8% (2) 0










1P = 0.078; 2P = 0.0087 by Fisher’s exact test. DM, dermatomyositis; PM,
polymyositis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus. SSc,
systemic sclerosis.
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[12]. The most striking aspect observed in this cohort
is that anti-MJ positive patients have higher prevalence
of malignancy [12]. Lack of malignancy in anti-MJ
positive patients in our cohort may be related to their
young age (average 37.6, range 24 to 56 with only 2/10
over age 50) compared to anti-MJ (+) patients with
malignancy reported (ages 54 to 68) [12]. This may be
similar to a strong association of anti-p155/140 with
malignancy in middle- to old-age DM but not in chil-
dren or young adults [19,20].
Anti-MJ antibodies are the most prevalent specificity
(30% in DM and 17% in PM/DM) in this Italian cohort,
followed by other known MSAs, such as anti-Jo-1 and
-Mi-2 (Table 1). The prevalence of anti-MJ in the pre-
sent study is similar to two juvenile DM studies per-
formed in Argentine [6] and UK/Ireland [5]. However,
our study is the first report on high prevalence of anti-
MJ antibodies in a cohort of adult patients with PM/
DM vs only 1.6% to 3% in PM/DM or 1.6% to 6% in
DM in other reports [11,12]. This could be due to dif-
ferent ethnic background, techniques, or other reasons.
Genetic and/or environmental factors within Caucasians
may be important variables, since the prevalence of anti-
MJ in American Caucasian adults is low [21]. In fact, we
have recently collected data on the different prevalence
of autoantibodies in American Caucasian patients fol-
lowed in our center, and only 3/73 (4%; all three DM
cases) were anti-MJ (+) [21]. Two additional anti-MJ (+)
cases were identified in a male Hispanic and a male
African American DM patient. All of the five American
anti-MJ (+) cases have DM features similar to those
identified in the Italian cohort. Significant differences
within Caucasians in prevalence of scleroderma-related
autoantibodies are also reported [22]. In the same way,
Figure 1 Detection of anti-MJ antibodies. A. Immunoprecipitation of anti-MJ and other autoantibodies that recognize proteins of
similar molecular weight. 35S-methionine labeled K562 cell extract was immunoprecipitated by human sera and analyzed by 8% SDS-PAGE.
Anti-MJ serum immunoprecipitates a ~140 kDa protein (arrow), which is different from the mobility of other known autoantigens. Reference sera
for anti-MDA5, -MJ, -RNA helicase A (RHA), -p155/140, -Mi-2, OJ, and -RNA polymerases (RNAPs) are shown. NHS, normal human serum. B.
Immunoprecipitation of anti-MJ positive sera. 35S-methionine labeled K562 cell extract was immunoprecipitated using mouse anti-MORC3
monoclonal antibody (lane mAb MORC3), human anti-MJ positive sera (lanes 1 to 10) or a normal human serum (NHS), and analyzed by 8%
SDS-PAGE. MW, molecular weight marker. C. IP-Western blot of MJ. The identity of the 140 kDa protein as MJ/NXP-2/MORC3 was verified by IP-
Western. The MJ protein is indicated with the arrow. MJ, anti-MJ reference serum, lanes 1 to 10, anti-MJ positive Italian samples. NHS, normal
human serum. D. Immunofluorescence staining of anti-MJ positive sera. HEp-2 slides were stained with mouse anti-MORC3 monoclonal
antibody (a), human anti-MJ (+) sera (b) to (e), or normal human serum (f). Serum dilution, 1:80.
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another unusual result from our study is the low preva-
lence of anti-Jo-1 antibodies in the Italian cohort (10%;
6 PM cases), and this is different from the American
Caucasian cohort in which anti-Jo-1 was the most fre-
quent specificity [21]. It is not clear why these antibo-
dies have such a different prevalence according to the
cohorts studied, but also in this case we can hypothesize
technical issues or factors involved in the disease
pathogenesis.
The majority (8/10) of anti-MJ (+) patients has DM,
consistent with data in previous cohorts [5,6,12]. Two of
our patients with anti-MJ can be classified as juvenile
onset DM, but even in the cases of adult onset, anti-MJ
(+) patients have younger onset of DM, compared with
anti-MJ (-) patients (Table 2). We were also able to
identify specific clinical features in our anti-MJ (+)
patients, who are characterized by severe skin disease
and extensive calcinosis, in the absence of internal
organ involvement. Myositis is usually well responsive
to treatment, and CPK levels tend to normalize quickly
after starting therapy (data not shown). These features
are similar to those reported in a cohort of British JDM
patients [5], but different from the results of another
study in Argentinian juvenile myositis [6], even if the
patients of this cohort were defined as ‘Argentine Cau-
casian’ due to the Spanish or Italian descent. This study
shows that anti-MJ (+) Argentinian patients mainly had
muscle contractures, atrophy and significant compro-
mise of the functional status, which are not seen in our
Italian cohort of adult PM/DM. The clinical expression
of PM/DM associated with anti-MJ (+) antibodies is
very peculiar when considering juvenile or adult onset
of disease.
The target recognized by anti-MJ antibodies was iden-
tified as a protein called NXP-2 (also known as
MORC3) [7], involved in transcriptional regulation and
activation of the tumor suppressor p53, which prevents
cell proliferation by inducing cellular senescence [8,10].
Previous IIF studies showed that NXP-2/MORC3 loca-
lizes to both PML nuclear bodies and the nucleoplasm
[10]. In the IIF study of our cohort of adult Italian PM/
DM, only 60% of anti-MJ (+) had nuclear dots consis-
tent with PML bodies. One possible explanation for this
partial positivity is that the MJ antigens in PML bodies
are not well recognized by certain human autoantibo-
dies, maybe due to denaturation by fixation of ANA
slides, poor reactivity with post-translationally modified
forms that accumulate in PML bodies [8], interference
by other proteins, low titer of the antibodies, or other
reasons. The link between NXP-2/MORC3, autoanti-
body production and disease development is not clear
yet. The report of NXP-2 as a SUMO (small ubiquitin-
like modifier) target with a possible role in SUMO-
mediated transcriptional repression [23] is an interesting
link with disease mechanisms, because antibodies to
SUMO-1 activating enzyme (SAE) have been found in
DM [24], and the p155 and Mi-2 antigens could also be
involved in transcriptional regulation [25]. Nevertheless,
none of anti-MJ positive patients had anti-SAE antibo-
dies that immunoprecipitate 90 kD and 40 kD proteins
[24] (Figure 1B).
Conclusions
In summary, anti-MJ antibodies are the most prevalent
specificity in our cohort of adult Italian PM/DM
patients. This autoantibody is associated with specific
clinical features in DM patients, similar to those identi-
fied in British patients with JDM, such as severe calcino-
sis, skin disease but no internal organ involvement [5].
IIF cannot be considered as a screening or verification
method to identify anti-MJ (+) samples, as only some
anti-MJ (+) samples show a pattern consistent with
PML nuclear bodies. Nevertheless, anti-MJ should be
considered when PML body staining is seen in PM/DM
patients. Further studies in various ethnicities and with
larger cohorts of patients with anti-MJ antibodies are
required to better understand clinical associations, etio-
pathogenesis and mechanisms of disease development.
Abbreviations
ANA: antinuclear antibody; CPK: creatine phosphokinase; ELISA: enzyme-
linked immunosorbent assay; HRP: horseradish peroxidase; IgG:
immunoglobulin G; IIF: indirect immunofluorescence; ILD: interstitial lung
disease; IP: immunoprecipitation; JDM: juvenile dermatomyositis; kD:
kiloDaltons; mAb: monoclonal antibody; MSAs: myositis-specific
autoantibodies; OD: optical density; PM/DM: polymyositis/dermatomyositis;
Table 2 Demographic, clinical and laboratory features in








Mean age, ys (± SD) 37.6 (± 12) 54.6 (± 14.8) 0.0023
DM/PM/overlap (%) 80/20/0 40/48/13 DM 0.03
Clinical and laboratory data
Heliotrope rash 60% 19% 0.01
Calcinosis 30% 8% 0.09
Facial erythema 60% 33% ns
Gottron’s papules 20% 19% ns
Arthritis 20% 8% ns
Raynaud’s phenomenon 20% 27% ns
Heart involvement 0% 13% ns
Interstitial lung disease 0% 33% 0.048
Elevated CPK at last visit 0% 25% ns
1P values are by Fisher’s exact test except for mean age comparison by Mann-
Whitney. CPK, creatine phosphokinase; DM/PM, dermatomyositis/polymyositis;
ns, not significant; SD, standard deviation.
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PML: promyelocitic leukemia; SAE: small ubiquitin-like modifier-1 activating
enzyme; SD: standard deviation; SDS-PAGE: sodium dodecyl sulfate-
polyacrylamide gel electrophoresis; SUMO: small ubiquitin-like modifier.
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